D. Cowan

发表

Design and synthesis of conformationally constrained analogues of 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one (Ro 20-1724) as potent inhibitors of cAMP-specific phosphodiesterase.

J. Veal, F. Schoenen, J. Stafford, 1995, Journal of medicinal chemistry.

Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes.

M. J. Bishop, J. Ambroso, J. Collins, 2013, Journal of medicinal chemistry.

Screening And Design Of Tumor Necrosis Factor-: Converting Enzyme Inhibitors

M. Lambert, T. Tippin, R. Wiethe, 2000 .

TNFα converting enzyme

M. Lambert, S. Frye, M. Vitek, 1999 .

N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.

J. Warner, M. Lambert, T. Tippin, 2001, Bioorganic & medicinal chemistry letters.

Identification of potent, nonabsorbable agonists of the calcium-sensing receptor for GI-specific administration.

S. Roller, S. M. Sparks, Grace Chen, 2017, Bioorganic & medicinal chemistry letters.

Discovery of 4-Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38.

J. D. Stuart, L. Shewchuk, B. Shearer, 2015, Journal of medicinal chemistry.

The structure - Activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones

J. Lehmann, L. Moore, T. Willson, 1996 .

Enzymatic- and iridium-catalyzed asymmetric synthesis of a benzothiazepinylphosphonate bile acid transporter inhibitor.

J. A. Ray, Amy A Sarjeant, J. Collins, 2013, The Journal of organic chemistry.

Discovery, Synthesis, and Biological Evaluation of Thiazoloquin(az)olin(on)es as Potent CD38 Inhibitors.

J. D. Stuart, W. Harrington, B. Henke, 2015, Journal of medicinal chemistry.

Design of Selective and Soluble Inhibitors of Tumor Necrosis Factor-α Converting Enzyme (TACE)+

M. Lambert, A. Musso, M. A. Leesnitzer, 2001 .

Phosphodiesterase type IV (PDE IV) inhibition. Synthesis and evaluation of a series of 1,3,4-trisubstituted pyrrolidines

J. Stafford, D. Cowan, P. Domanico, 1995 .

The human ACC2 CT-domain C-terminus is required for full functionality and has a novel twist.

Shawn P. Williams, S. Short, T. Consler, 2009, Acta crystallographica. Section D, Biological crystallography.

Phosphodiesterase type IV inhibition. Structure-activity relationships of 1,3-disubstituted pyrrolidines.

F. Schoenen, J. Stafford, M. A. Leesnitzer, 1995, Journal of medicinal chemistry.

Substrate specificity and novel selective inhibitors of TNF-alpha converting enzyme (TACE) from two-dimensional substrate mapping.

M. Lambert, D. Kassel, R. Wiethe, 2005, Combinatorial chemistry & high throughput screening.

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.

J. Lehmann, L. Moore, T. Willson, 1996, Journal of medicinal chemistry.

Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes.

M. J. Bishop, J. Ambroso, J. Collins, 2013, Journal of medicinal chemistry.